We have a proven track record of success in drug discovery, drug development, FDA approval and commercialization.

Michela Gallagher, PhD is the Krieger-Eisenhower Professor of Psychological and Brain Science, heads the Neurogenetics and Behavior Center at Johns Hopkins University and has published over 250 peer-reviewed papers in the field of cognitive neuroscience. She is a Fellow of the American Association for the Advancement of Science, the American Psychological Association, the American Psychological Society. She is the 2018 recipient of the Melvin R. Goodes Prize for a lifelong commitment to Alzheimer’s drug discovery and development. She was the 2014 recipient of the Society for Neuroscience, Mika Salpeter Lifetime Achievement Award. Her work has been recognized by the American Psychological Association, D.O. Hebb Distinguished Scientific Contribution Award in 2010, a Freedom to Discover Award from the Bristol-Myers Foundation (2003-2008), and Senior Scientist Award from the Ellison Medical Foundation (2008-2012). She has served the on Boards of Scientific Counselors at the National Institute of Mental Health and the National Institute on Aging, the Scientific Advisory Board of the Stanley Center at the Broad Institute and the Advisory Board of DZNE, the German Center for Neurodegenerative Diseases. Prior to joining Johns Hopkins in 1997, Dr. Gallagher rose through the faculty ranks at University of North Carolina at Chapel Hill, where she was the Kenan Professor of Psychology. She earned her PhD in Physiological Psychology from University of Vermont and in 1968 earned her undergraduate degree from Colgate University as one of two women in the university’s first female graduating class.

Dr. Mohs now leads the AgeneBio clinical trial on the efficacy of AGB101 in patients with MCI due to AD. He is also P.I. on a NIIH award supporting the Phase 2b trial to include biomarker development using [¹⁸F]MK-6420 for tau PET imaging. Dr. Mohs served as Eli Lilly’s Vice President for Neuroscience Early Clinical Development and Distinguished Research Fellow within Lilly Research Laboratories, where he led a clinical development team targeting Alzheimer’s disease or other neurodegenerative diseases, pain, depression or schizophrenia. Previously, he was Professor in the Department of Psychiatry with the Mount Sinai School of Medicine and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. During this time, he was instrumental in designing clinical trials that led to the approval in the US and other countries of cholinergic drug treatments for Alzheimer’s disease. He has served as an advisor to many neuroscience research programs at universities in the United States and to several foundations supporting neuroscience research including the John D. and Catherine T. MacArthur Foundation, the Charles A. Dana Foundation and has recently been appointed to the Board of Governors for the Alzheimer’s Drug Discovery Foundation. Dr. Mohs received his PhD in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School.

She led the development of the proprietary formulation of AGB101, management of the Phase 1 with FDA review and completed manufacture of medical supplies for further clinical research. She has also led the GABA-A a5 PAM discovery program through preclinical development.
Dr. Rosenzweig-Lipson brings expertise with more than 25 years of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry. She spent her career focused on psychiatric and neurologic indications in industry, including American Cyanamid, American Home Products, Wyeth and Pfizer.